Radiation Oncology/Therapy: Page 239

U.S. awards $56.3M for radiation protection
By AuntMinnie.com staff writers
The U.S. Department of Health and Human Services has awarded $56.3 million in contracts toward the development of new drugs to treat injuries associated with acute radiation syndrome.
September 28, 2011
Calypso obtains IDE approval
By AuntMinnie.com staff writers
Electromagnetic localization technology developer Calypso Medical Technologies has received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration for a clinical study evaluating real-time tracking of lung cancer tumors during radiation delivery.
September 28, 2011
Vision RT adds U.S. customers
By AuntMinnie.com staff writers
U.K. radiation therapy software developer Vision RT has added several U.S. clients to its customer base.
September 27, 2011
ASTRO: Chemo + RT increases tumor response
By AuntMinnie.com staff writers
Rectal cancer patients treated with a new combination of chemotherapy and radiation therapy (RT) before undergoing surgery have an 88% chance of surviving the cancer three years following treatment, according to trial results being presented at the American Society for Radiation Oncology (ASTRO) annual meeting.
September 27, 2011
ASTRO: IMRT produces less rectal toxicity in prostate cancer
By Cynthia E. Keen
Intensity-modulated radiation therapy (IMRT) causes fewer bowel and rectal toxicities than 3D conformal radiation therapy, according to study findings to be presented October 3 at the plenary session of the American Society for Radiation Oncology (ASTRO) annual meeting.
September 27, 2011
ViewRay awarded UCLA order
By AuntMinnie.com staff writers
Image-guided therapy developer ViewRay has taken an order from the University of California, Los Angeles (UCLA) Health System and Jonsson Comprehensive Cancer Center for its new research radiation therapy system.
September 27, 2011
Hypofractionated RT works for prostate cancer
By AuntMinnie.com staff writers
A hypofractionated course of radiation therapy is as effective as conventional radiation therapy in reducing intermediate- to high-risk prostate cancer recurrence, according to five-year outcome results of a clinical trial to be presented at next week's American Society for Radiation Oncology annual meeting.
September 26, 2011
Vision RT opens N. American support center
By AuntMinnie.com staff writers
U.K. radiation therapy software developer Vision RT has opened a North American customer support center in Ellicott City, MD.
September 26, 2011
IsoRay reports cesium-131 milestone
By AuntMinnie.com staff writers
Medical isotope developer IsoRay Medical said that the first treatment of metastasized brain cancer using its cesium-131 brachytherapy seeds was performed at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
September 25, 2011
Accuray adds to executive lineup
By AuntMinnie.com staff writers
Radiation oncology firm Accuray has named Kelly Londy as senior vice president and chief commercial officer, effective October 1.
September 20, 2011
Bionix adds Medspira's Breath Hold
By AuntMinnie.com staff writers
Radiation therapy accessories provider Bionix Radiation Therapy has added Breath Hold, an interactive breath-hold control monitoring system from Medspira, as an accessory to its Omni V patient positioning system.
September 20, 2011
Peptide therapy reduces tumor size, side effects
By AuntMinnie.com staff writers
Dutch researchers are reporting on a peptide receptor radiolabeled therapy that can decrease both tumor size and the severity of side effects in cancer patients in this month's issue of the Journal of Nuclear Medicine.
September 20, 2011
Previous Page
Page 239 of 468
Next Page